Mitzner W. Emphysema: a disease of small airways or lung parenchyma? The New England journal of medicine. 2011;365(17):1637.
2. Vogelmeier CF, Criner GJ, Martinez FJ, Anzueto A, Barnes PJ, Bourbeau J, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease 2017 report. GOLD executive summary. American journal of respiratory and critical care medicine. 2017;195(5):557-82.
3. Longo DL, Fauci AS, Kasper DL, Hauser SL, Jameson JL, Loscalzo J. Harrison's principles of internal medicine: Mcgraw-hill New York; 2012.
4. Rammaert B, Verdier N, Cavestri B, Nseir S. Procalcitonin as a prognostic factor in severe acute exacerbation of chronic obstructive pulmonary disease. Respirology. 2009;14(7):969-74.
5. O’Donnell DE, Laveneziana P, Webb K, Neder JA. Chronic obstructive pulmonary disease: clinical integrative physiology. Clinics in chest medicine. 2014;35(1):51-69.
6. Chang C-H, Tsao K-C, Hu H-C, Huang C-C, Kao K-C, Chen N-H, et al. Procalcitonin and C-reactive protein cannot differentiate bacterial or viral infection in COPD exacerbation requiring emergency department visits. International journal of chronic obstructive pulmonary disease. 2015;10:767.
7. Forey BA, Thornton AJ, Lee PN. Systematic review with meta-analysis of the epidemiological evidence relating smoking to COPD, chronic bronchitis and emphysema. BMC pulmonary medicine. 2011;11(1):36.
8. Andersen ZJ, Hvidberg M, Jensen SS, Ketzel M, Loft S, Sørensen M, et al. Chronic obstructive pulmonary disease and long-term exposure to traffic-related air pollution: a cohort study. American journal of respiratory and critical care medicine. 2011;183(4):455-61.
9. Ergan B, Şahin AA, Topeli A. Serum procalcitonin as a biomarker for the prediction of bacterial exacerbation and mortality in severe COPD exacerbations requiring mechanical ventilation. Respiration. 2016;91(4):316-24.
10. Daubin C, Parienti J-J, Vabret A, Ramakers M, Fradin S, Terzi N, et al. Procalcitonin levels in acute exacerbation of COPD admitted in ICU: a prospective cohort study. BMC infectious diseases. 2008;8(1):145.
11. Vagaggini B, Costa F, Antonelli S, De Simone C, De Cusatis G, Martino F, et al. Clinical predictors of the efficacy of a pulmonary rehabilitation programme in patients with COPD. Respiratory medicine. 2009;103(8):1224-30.
12. Li Y, Xie L, Xin S, Li K. Values of procalcitonin and C-reactive proteins in the diagnosis and treatment of chronic obstructive pulmonary disease having concomitant bacterial infection. Pakistan journal of medical sciences. 2017;33(3):566.
13. Giorgi-Pierfranceschi M, Cravo J, Dentali F, Esquinas AM. Is Procalcitonin Really Useful for Diagnosis and Prognosis of COPD Exacerbations Requiring Mechanical Ventilation? Respiration. 2017;93(2):151-2.
14. Ebrahimzadeh F, Rezaeetalab F, Matoofi A. The Relationship between Serum N-terminal Pro B-type Natriuretic Peptide Level and the Severity of Chronic Obstructive Pulmonary Disease Exacerbation. 2018.
15. Stolz D, Christ-Crain M, Morgenthaler NG, Leuppi J, Miedinger D, Bingisser R, et al. Copeptin, C-reactive protein, and procalcitonin as prognostic biomarkers in acute exacerbation of COPD. Chest. 2007;131(4):1058-67.